СТОИМОСТЬ РЕВМАТОИДНОГО АРТРИТА И ЭКОНОМИЧЕСКАЯ ЦЕЛЕСООБРАЗНОСТЬ ТЕРАПИИ

1. <div><p>Авксеньтьева М.В. Воробьев В.Б., Герасимов В.Б., Горохова С.Г., Кобина С.А. Экономическая оценка эффективности лекарственной терапии. “Ньюдиамед”. М. 2000.</p><p>Габуева Л.А. Экономика ЛПУ: экономическая эффективность и бизнес планирование. М.; ГРАНТь, 2001,</p><p>Насонов Е.Л. Целебрекс-доказанная эффективность и безопасность (новые данные), Тер. архив. 2001.5,57-61.</p><p>Насонова В.А. Фоломеева О.М., Эрдес Ш. Социальная значимость заболеваний ревматического круга в России. Научно-практич. ревматол., 2001, в печати</p><p>Цветкова Е.С., Алексеева Л.И., Балабанова P.M., Чичасова Н.В., Шостак Н.А. Эффективность и переносимость целебрекса при остеоартрозе. Тер.архив, 2001.5,61-63.</p><p>Albers J.M.С., Paimela L., Kurki P. et al. Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis.,2001,60,453-8.</p><p>Anis A.H., Tugwell P.X., Wells G.A., Stewart D.G. A cost- effectiveness analysis of cyclosporine in rheumatoid arthritis. J Rheumatol.,1996,23,609-16.</p><p>Barrett E.M., Scott D.G.I., Wiles N.J., Symmons D.P.M. The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. Rheumatol.,2000,39,1403-9.</p><p>Bathon J.M. Marlin R.W., Fleischmann R.M. et al. A comparison of elanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med., 2000, 343,1585-93.</p><p>Boers М., Verhoeven A.C., Markusse H.M. el al. Randomised comparison of combined step down prednisolone, methotrexate and sulphasalazine with sulphasala- zine alone in early rheumatoid arthritis. Lancet, 1997,350,309-18.</p><p>Burke Т.А., Zabinski R.A. Pettitt D., Maniadakis N. Maurath C.J., Goldstein A. framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or cele- coxib in the treatment of arthritis. Pharmacoeconom., 2001,19, suppl., 1,33-47.</p><p>Callahan L.F. The burden of rheumatoid arthritis: facts and figures. J Rheumatol., 1998, 25, suppl., 53, 8-12.</p><p>Chancellor J.V., Hunsche E., de Cruz E., Sarasin F.P. Economic evaluation of celecoxib, a new cyclo-oxygen- ase 2 specific inhibitor, in Switzerland. Pharmacoeconom., 2001,19, suppl, 1,59-75.</p><p>Choi H.K., Seeger J.D., Kuntz K.M. A cost effectiveness analysis of treatment options for patients with methotr- exale-resistant rheumatoid arthritis. Arthr. Rheum., 2000, 43,2316-27.</p><p>Clarke A.E., Zowall H., Levinton C., Assimakopoulos H. , Sibley J.T., Haga М., et al.: Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12yearstudy. J Rheumatol., 1997,24,10511060.</p><p>Cooper N.J. Economic burden of rheumatoid arthritis: a systematic review. Rheumatol,, 2000, 39,28-33.</p><p>Drummond M.F. Health economic models: a question of balance—summary of an open discussion on the phar- macoeconomic evaluation of non-steroidal anti-inflammatory drugs. Rheumatol., 2000, 39, Suppl. 2, 3-12.</p><p>Drummond M.F., Jefferson T.O. Guidelines for authors and peer reviewers of economic submissions to the BMJ. Br MedJ., 1996,313,275-83.</p><p>Gabriel S.E., Crowson C.S., Campion M.E., O’Fallon W.M. Direct medical costs unique Lo people with arthritis. J Rheumatol., 1997, 24, 719-25.</p><p>Gabriel S.E., Crowson С.S., Campion М.Е., O’Fallon W.M. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol. 1997, 24 ,43-8.</p><p>Gabriel S.E., Crowson C.S., Luthra H.S., Wagner J.L., O’Fallon W.M. Modeling the lifetime costs of rheumatoid arthritis. J Rheumatol., 1999,26, 1269-74.</p><p>Haglund U. Svarvar P. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis Rheumatol. (Oxford), 2000, 39, suppl 2, 51-6.</p><p>Kavanaugh A., Heudebert G., Cush J., Jain R. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model, Semin Arthritis Rheum.,1996, 25, 297-307. '</p><p>Kobelt G., Eberhardt K., Jonsson L., Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 1999, 42, 347-56.</p><p>Lambert С. M. Medical therapy for rheumatoid arthri- tis-value for money? Rheumatol., 2001, 40, 961-964.</p><p>Lambert C.M,, Hurst N.P. Health economics as an aspect of health outcome: basic principles and application in rheumatoid arthritis. Br J Rheumatol., 1995,35,774-80.</p><p>Lambert C.M., Hurst N.P., Forbes J.F., Lochhead A., Macleod М., Nuki G. Is day care equivalent to inpatient care for active rheumatoid arthritis? Randomized controlled clinical and economic evaluation. Br Med J., 1998, 316,965-969.</p><p>Lambert M. Medical therapy for rheumatoid arthritis— value for money? Rheumatol.? 2001, 40, 961-964.</p><p>Lanes S.F., Lanza L.L., Radensky P.W., Yood R.A., Meenan R.F., Walker A.M., Dreyer N.A. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthr. Rheum. 1997, 40, 14751481.</p><p>Lipsky P.E., van der Heijde D.M., Clair E.W. el al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med., 2000, 343, 1594-602.</p><p>Lubeck D.P., Spitz P.W., Fries J.F, Wolfe F., Mitchell D.M., Roth S.H. A multi-center study of annual health service utilization and costs in rheumatoid arthritis. Arthr. Rheum., 1986, 29, 488-93.</p><p>Maetzel A., Ferraz M.B., Bombardier C.: The cost-efTec- tiveness of misoprostol in preventing serious gastrointestinal events associated with the use ofnonsteroidai antiinflammatory drugs. Arthritis Rheum., 1998, 41, 16-25.</p><p>McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol., 1996.35, 781-90.</p><p>Meenan R.F., Yelin E.H., Henke C.J., Curtis D.L., Epstein W.V. The costs of rheumatoid arthritis: a patient- orientated study of chronic disease costs. Arthritis Rheum., 1978. 21, 827-33.</p><p>O'Brien B. Statistical analysis of cost effectiveness data. J Rheumatol. 1999,26, 207S-80.</p><p>Paulus H.E Current therapeutic options; non-biologic agents. In: Rheumatoid arthritis: epidemiology, pathogenesis and treatment. London: ReMedica, 2001, 45-70.</p><p>Pincus T„ Marcum S.B., Callahan L.F. Long term drug therapy for rheumatoid arthritis in seven Rheumatol, private practices. 2. Second line drugs and prednisolone. J Rheumatol., 1992, 19,1 885-94. 3S. Praemer A., Furner S., Rice D. Musculoskeletal conditions in the United States. American Academy of Orthopedic Surgeons, 1999, 139-162</p><p>Prasker M.J., Meenan R.F. The total cost of drug therapy for rheumatoid arthritis: a model based on costs of drug, monitoring and toxicity. Arthr. Rheum., 1995, 38, 318-25.</p><p>Ruof J., Hulsemann J., Stuck G. Evaluation of costs in rheumatic diseases: a literature review. Current Opinion in Rheumatol., 1999. II, 104-109.</p><p>Sonnenberg F.A., Beck J.R. Markov models in medical decision making. Med Decis Making 1993,13,322-38,</p><p>Stone C,E. The lifetime costs of rheumatoid arthritis. J Rheumatol., 1984, 11,819-27.</p><p>Van Jaarsveld C.H., Jacobs J.W., Schrijvers A.J., Heu- rkens A.H., Haanen H.C., Bijisma J.W. Direct cost of rheumatoid arthritis during the first six years: a cost-of- illness study. Br J Rheumatol., 1998, 37, 837-47.</p><p>Verhoeven H.M., Bibo J.C., Boers M. el al. Cost effectiveness and cost utility of combination therapy in early rheumatoid arthritis: randomised comparison of combined step down prednisolone, methotrexate and sul- phasalazine with sulphasalazine alone. Br J Rheumatol. 1998,37,1102-9.</p><p>Walan A, Wahlqvist P. Pharmacoeconomic aspects of non-steroidal anti-inflammatory drug gastropathy. Ital J Gastroenterol Hepatol., 1999, 31, suppl I, 79-88.</p><p>Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol., 1995, 9.619-32.</p><p>Wolfe F. Hawley D.J., Cathey M.A. Termination of slow acting anti-rheumatic therapy in rheumatoid arthritis: a 14 year prospective evaluation of 1017 consecutive starts. J Rheumatol., 1990, 17,994-1002.</p><p>Wolfe F., Mitchel D.M., Sibley J.T. et al. The mortality of rheumatoid arthritis. Arthr. Rheum., 1994, 37, 481-94</p><p>Yelin E., Callahan L.F., The economic cost and psycho- sological impact of musculoskeletal conditions. Arthr. Rheum., 1995,38,1351-62.</p><p>Yelin E., Wanke L.A. An assessment of the annual and long-term direct costs of rheumatoid arthritis. The impact of poor function and functional decline. Arthr. Rheum., 1999,42,1209-18.</p></div><br />